Sydney, Australia 8 November 2017 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that site activation at the Children’s Hospital at Westmead in Sydney has been completed and recruitment has commenced for its SARTATE™ Kids trial.
Clarity’s SARTATE™ Kids trial is a Positron Emission Tomography (PET) imaging trial of paediatric patients with high-risk neuroblastoma using Copper-64 SARTATE™. It is a multi-centre, open-label, non-randomised Phase 1-2a imaging trial in 10 patients that is being led by Professor Robert Howman-Giles at the Children’s Hospital at Westmead. The Children’s Hospital is one of the largest paediatric centres in New South Wales, which provides excellent care for children from Australia and across the Pacific Rim. Additional sites in Australia and the USA will be activated over the coming months in order to fast-track the completion of this trial. The data from this trial will enable Clarity to progress Copper-67 SARTATE™ trials for the therapeutic treatment of neuroblastoma in children.
Neuroblastoma is a disease that occurs most often in infants and young children, usually in children younger than 5 years old. It is the most common type of cancer to be diagnosed in the first year of life and accounts for around 13% of paediatric cancer mortality. High-risk neuroblastoma accounts for approximately 45% of all neuroblastoma cases. Patients with high-risk neuroblastoma have the lowest 5-year survival rates at 40%-50%.
Dr Alan Taylor, Clarity’s Executive Chairman, commented on the site activation “We are very excited to commence this trial at the Children’s Hospital at Westmead and are looking forward to completing this important work. Clarity is well positioned with its technology to pave the way for better therapies for children with cancer by trying to improve survival rates and significantly reduce long-term side effects. The ultimate goal is to ensure that these children not only survive, but live better lives post treatment”.
About Clarity
Clarity Pharmaceuticals is a personalised medicine company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceutical technology, developing targeted therapies and assisting in the drug development pipeline of novel therapies for companies globally.
www.claritypharmaceuticals.com
Media Contact
Dr Alan Taylor
Executive Chairman
Ph: +61 (0)413 871 165
E: ataylor@claritypharm.com
